Newsfile Corp
28 Sept 2026, 18:45 UTC · 1h ago
Verdict
Headline takes no side. We score HEM +0.60 across two claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Hemostemix has applied under The Bahamas' Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I basket clinical trial evaluating VesCell in angina, vascular dementia, and pain.
Newpress release dated September 28, 2026
More positive than 79% of claims this week
Hemostemix will present at the Centurion One Capital 4th Annual Bahamas Summit from October 19 to October 21, 2026.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
So whatThe event provides a concentrated window for institutional fundraising and potential private placement interest in Q4.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
The company is presenting at an exclusive investor summit and highlighting positive clinical data and commercialization efforts for its VesCell therapy.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
—
No price for HEM right now — the quote feed didn't answer.
HEM chart →
